Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Faron Pharmaceuticals Oy LSE:FARN London Ordinary Share FI4000153309 ORD NPV (DI)
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -20.00 -6.67% 280.00 275.00 285.00 300.00 270.00 300.00 38,480 16:24:53
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -11.2 -26.2 - 131

Faron Pharmaceuticals Oy Faron to Present at H.C. Wainwright Conference

09/09/2020 12:00pm

RNS Non-Regulatory


TIDMFARN

Faron Pharmaceuticals Oy

09 September 2020

Faron Pharmaceuticals Ltd

("Faron" or the "Company")

Faron Pharmaceuticals to Present at the Virtual H.C. Wainwright 22(nd) Annual Global Investment Conference

TURKU - FINLAND, September 9, 2020 - Faron Pharmaceuticals Ltd ( " Faron") (LON: FARN), the clinical stage biopharmaceutical company , today announced that Dr. Markku Jalkanen, Chief Executive Officer of Faron Pharmaceuticals, will present at the virtual H.C. Wainwright 22(nd) Annual Global Investment Conference on Wednesday, September 16, 2020 at 11:00 a.m. ET.

To access a live webcast and subsequent archived recording of the presentation, please visit the "Investors" section on Faron's website at https://www.faron.com/investors

ENDS

For more information please contact:

Stern Investor Relations, Inc.

Julie Seidel, Naina Zaman

Phone: +(1)212 362 1200

Email: faron@sternir.com

Consilium Strategic Communications

Mary-Jane Elliott, David Daley, Lindsey Neville

Phone: +44 (0)20 3709 5700

E-mail: faron@consilium-comms.com

About Faron Pharmaceuticals Ltd

Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen, its precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development. Currently in phase I/II clinical development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, Clevegen has potential as a single-agent therapy or in combination with other standard treatments including immune checkpoint molecules. Traumakine, the Company's pipeline candidate to prevent vascular leakage and organ failures, has completed a phase III clinical trial in Acute Respiratory Distress Syndrome (ARDS). Plans for its future development are being finalised to avoid interfering steroid use together with Traumakine. Faron is based in Turku, Finland. Further information is available at www.faron.com

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Private Policy.

END

NRAKKCBBKBKDCCK

(END) Dow Jones Newswires

September 09, 2020 07:00 ET (11:00 GMT)

1 Year Faron Pharmaceuticals Oy Chart

1 Year Faron Pharmaceuticals Oy Chart

1 Month Faron Pharmaceuticals Oy Chart

1 Month Faron Pharmaceuticals Oy Chart
ADVFN Advertorial
Your Recent History
LSE
FARN
Faron Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20201029 06:39:07